Saturday 17 October 2026
Export IMTX’s income statement to Excel — free account
Immatics N.V.
IMTX Healthcare Biotechnology
Immatics N.V.’s revenue for fiscal 2025 (year ended December 2025) was $54.6 million, down 67.6% from fiscal 2024. In the quarter to June 2026, revenue grew 97.7%, EPS grew 19.7% and free cash flow fell 44.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
6.72
0.42
−5.88%
Follow IMTX
| Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | 4 | 4 | 7 | 3 | 5 | 3 |
P/E ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 11.43 | 0.00 | 39.50 | 0.00 |
Altman Z-Score |
— | 0.65 | (1.44) | (0.42) | (2.50) | 1.46 | 0.15 | 3.26 | 6.75 |
P/S ratio |
— | 0.00 | 0.00 | 13.28 | 20.56 | 3.16 | 14.78 | 4.46 | 23.53 |
P/FCF ratio |
— | 0.00 | 4.85 | 0.00 | 0.00 | 5.82 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | (1.47) | (4.89) | (2.43) | (11.05) | 2.00 | (0.56) | 7.13 | 5.14 |
Beneish M-Score |
— | — | (4,924.98) | (4.74) | (2.87) | (0.61) | 5.39 | 0.07 | (1.36) |
P/Operating CF |
— | 0.00 | 4.83 | (33.14) | (26.67) | (21.31) | 10.05 | (12.22) | (20.74) |
P/B ratio |
— | 6.13 | 0.00 | 4.97 | 29.70 | 2.57 | 3.54 | 1.21 | 2.35 |
Price to Tangible BV |
— | 6.13 | 0.00 | 5.01 | 31.42 | 2.58 | 3.57 | 1.21 | 2.35 |
EV/Sales |
— | 0.00 | 0.00 | 7.96 | 16.73 | 2.30 | 10.73 | 2.94 | 16.36 |
EV/EBITDA |
— | 0.00 | 0.00 | 0.00 | 0.00 | 10.79 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
— | 0.00 | 3.39 | (3.63) | (7.11) | 3.98 | 31.78 | (2.90) | (4.47) |
EV/FCF |
— | 0.00 | 3.39 | (3.26) | (6.65) | 4.24 | (46.06) | (2.62) | (4.30) |
Quick Ratio |
— | 655.30 | 1.51 | 3.44 | 1.40 | 1.41 | 1.42 | 3.57 | 8.18 |
Current Ratio |
— | 266.46 | 1.79 | 3.94 | 1.60 | 3.54 | 2.87 | 9.26 | 11.72 |
Net Debt/EBITDA |
— | 0.04 | 3.54 | 3.18 | 1.64 | (4.02) | 2.31 | 8.97 | 2.04 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.05 | 0.13 | 0.16 | 0.18 | 0.57 | 0.12 | 0.26 | 0.08 |
Operating CF/Net income |
— | (0.66) | (2.25) | 0.37 | 0.88 | 2.67 | (0.19) | (10.38) | 0.90 |
Capex/Depreciation |
— | (0.19) | (0.55) | (1.70) | (1.08) | (0.88) | (4.26) | (1.35) | (0.55) |
Interest Coverage |
— | (213.72) | (125.05) | (6.93) | (50.00) | 3.62 | (14.45) | (29.23) | (4.96) |
| — | 106.81% | 176.20% | (722.34%) | (166.40%) | 31.24% | (44.84%) | 3.80% | (38.00%) | |
| — | (43.13%) | (22.54%) | (117.79%) | (47.88%) | 12.42% | (21.39%) | 2.52% | (31.99%) | |
ROIC |
— | (565.68%) | 0.00% | 0.00% | 0.00% | 28.96% | (961.55%) | (7.14%) | (82.33%) |
Return on Tangible Assets |
— | (532.24%) | (53.13%) | (122.98%) | (138.14%) | 13.20% | (28.82%) | 2.49% | (39.05%) |
Average Days of Receivables |
— | 201.21 | 18.93 | 14.60 | 7.16 | 2.35 | 27.67 | 13.72 | 46.12 |
Research and Development Expense of Revenue |
— | 901.09% | 217.31% | 214.65% | 251.92% | 61.78% | 219.76% | 95.02% | 380.87% |
Selling, General and Administrative Expense of Revenue |
— | 203.34% | 63.72% | 109.38% | 97.25% | 20.90% | 70.74% | 29.81% | 106.05% |
Intangible Assets out of Total Assets |
0.00 | 0.01 | 0.01 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | 39.20% | 4.62% | 73.44% | 75.95% | 13.06% | 38.34% | 11.32% | 31.11% |
Graham Net Nets |
— | (4.55) | (0.15) | 0.17 | 0.00 | 0.33 | 0.21 | 0.73 | 0.38 |
Graham Number |
— | 0.00 | 5.22 | 0.00 | 0.00 | 7.51 | 0.00 | 4.88 | 0.00 |
Earnings Yield |
— | (6.02%) | (9.44%) | (44.42%) | (12.50%) | 8.75% | (12.13%) | 2.53% | (17.52%) |
Free Cash Flow Yield |
— | 0.00% | 20.62% | (18.39%) | (12.23%) | 17.19% | (1.58%) | (25.12%) | (16.15%) |
Revenue per Share |
— | 0.11 | 0.56 | 0.65 | 0.65 | 2.71 | 0.73 | 1.59 | 0.45 |
Operating CF per Share |
— | 0.63 | 2.14 | (1.78) | (1.54) | 1.57 | 0.24 | (1.62) | (1.63) |
Capex per Share |
— | (0.01) | (0.06) | (0.16) | (0.11) | (0.10) | (0.41) | (0.17) | (0.06) |
Free Cash Flow per Share |
— | 0.61 | 2.08 | (1.94) | (1.64) | 1.47 | (0.17) | (1.79) | (1.70) |
Cash per Share |
— | 0.04 | 3.12 | 4.32 | 2.50 | 2.33 | 2.94 | 2.42 | 3.20 |
Shareholders Equity per Share |
— | 0.15 | (1.23) | 2.17 | 0.45 | 3.34 | 3.02 | 5.88 | 4.48 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 0.15 | (1.23) | 2.17 | 0.45 | 3.34 | 3.02 | 5.88 | 4.48 |
Free Cash Flow |
— | 20.27 | 68.83 | (93.13) | (103.45) | 99.00 | (13.61) | (188.84) | (207.53) |
Working Capital |
— | 1.33 | 54.70 | 178.38 | 67.51 | 285.21 | 316.92 | 607.67 | 521.57 |
Capital Expenditures |
— | (0.41) | (2.14) | (7.52) | (6.69) | (6.49) | (33.34) | (17.83) | (7.70) |
Net Current Asset Value |
— | (139.49) | (51.11) | 88.60 | 1.92 | 192.28 | 178.03 | 549.98 | 481.72 |
EV/EBIT |
— | 0.00 | 0.00 | 0.00 | 0.00 | 13.30 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
— | 0.11 | 0.12 | 0.24 | 0.16 | 0.04 | 0.57 | 0.11 | 0.14 |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | 0.00 | 18.25 | 0.00 | 0.00 | 0.00 |
| Other line items | |||||||||
Depreciation/Fixed assets |
— | 0.48 | 0.82 | 0.56 | 0.50 | 0.52 | 0.17 | 0.24 | 0.29 |
Cash ROIC |
— | 327.04% | 110.10% | (29.87%) | (55.67%) | 25.98% | (2.84%) | (21.50%) | (22.10%) |
Accounts Receivable Turnover |
— | 1.47 | 12.16 | 28.32 | 39.99 | 184.17 | 20.87 | 31.32 | 8.25 |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
— | 2.57 | 1.52 | 1.10 | 1.03 | 0.99 | 2.80 | 5.38 | 6.62 |
Average Payables |
— | 6.38 | 5.94 | 8.57 | 11.90 | 13.75 | 20.52 | 24.84 | 21.85 |
Average Assets |
— | 72.91 | 140.05 | 194.46 | 230.63 | 318.15 | 490.81 | 652.62 | 694.76 |
Average Common Equity |
— | (29.44) | (17.92) | 31.71 | 66.36 | 126.53 | 234.10 | 432.82 | 584.87 |
Columns are period end dates